The Long-Term Outcomes of Patients with Chemotherapy-Induced Cardiomyopathy Undergoing Heart Transplantation
Purpose: Chemotherapy-induced cardiomyopathy (CCMP) is observed in up to 10% of cancer survivors. Progression into end-stage heart failure occurs in 2-4% of those patients. In individuals in complete remission who develop end-stage heart failure an orthotopic heart transplantation (OHT) is a viable option. The data on the contemporary long-term post-OHT outcomes in CCMP patients is scarce.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: , A. Carmona Rubio, J. Herrmann, K. Meleveedu, O. Ali, W. Tang Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiomyopathy | Chemotherapy | Heart | Heart Failure | Heart Transplant | Lung Transplant | Transplant Surgery | Transplants